PhaseBio said the second slice of $15m from the B round followed the completion of drug milestones.

PhaseBio Pharmaceuticals, a US-based drug developer for diabetes (pictured), has drawn down the second tranche of its $25m series B round that closed in January.

PhaseBio said the second slice of $15m from the B round followed the completion of phase one and 2a testing of its Glymera (PB1023) drug to treat type 2 diabetes and moving the company’s second lead compound toward an

Investigational New Drug filing planned for next year.

PhaseBio raised the $25m from corporate venturing…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?